Prescription medicine
Finerenone Brand names: Kerendia
Finerenone (Kerendia) is a prescription medicine with an FDA approval on record since 2021. No generic is listed; pharmacies paid $22.86 per Kerendia 10 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the finerenone FDA label on DailyMed (effective August 28, 2025, Bayer HealthCare Pharmaceuticals Inc.); the NDA 215341 record on Drugs@FDA; every finerenone label on DailyMed.
Highlights of the record
FDA label of August 28, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageKerendia is indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).
Forms and strengths
- 10 mg
- 20 mg
- 40 mg
Film-coated tablet; tablet.
On the market
- Earliest approval on file
- July 9, 2021 Kerendia, Bayer Hlthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- July 29, 2035 Kerendia tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $22.86 per tablet Kerendia 10 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is finerenone used for?
From the label: indications and usageKerendia is indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. […]
Conditions named in the indications of finerenone's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Nonsteroidal Mineralocorticoid-Receptor Antagonist.
Source: FDA drug label (Kerendia), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2025 (SPL set fc726765-5d5a-4d6e-b037-b847bda9fb7c), via openFDA; the full label on DailyMed
Is there a generic for finerenone (Kerendia)?
No generic finerenone is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 2 patents for Kerendia tablets: the compound patent runs to July 29, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2021 earliest approval on file
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for finerenone (Kerendia)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $22.86 per Kerendia 10 mg tablet, up 4% from $21.94 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Kerendia 20 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Kerendia 10 mg tablet | Brand | $22.86 per tablet | $685.67 | +4% |
| Kerendia 20 mg tablet | Brand | $22.85 per tablet | $685.55 | +4% |
| Kerendia 40 mg tablet | Brand | $22.86 per tablet | $685.93 | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the finerenone label say about other medicines?
The finerenone label names no other medicine on this site. The labels of 5 other medicines name finerenone. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Other labels that name finerenone
Source: FDA drug label (Kerendia), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2025 (SPL set fc726765-5d5a-4d6e-b037-b847bda9fb7c), via openFDA; the full label on DailyMed
What else is labeled for the same conditions as finerenone?
1 other medicine is given the same way (oral) and in the same FDA class as finerenone or labeled mainly for the same use (chronic kidney disease), the same class first. Chronic kidney disease lists all 8 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Dapagliflozin | Chronic kidney disease | 22 labelers | $0.184 per tablet 10 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Check an interaction
- what two or more labels say about each other